Get the Stockscreener App
23.07
1.24%
-0.29
Alumis Inc stock is traded at $23.07, with a volume of 1.09M.
It is down -1.24% in the last 24 hours and down -17.84% over the past month.
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.
See More
Previous Close:
$23.36
Open:
$23.19
24h Volume:
1.09M
Relative Volume:
0.39
Market Cap:
$2.93B
Revenue:
$24.05M
Net Income/Loss:
$-243.33M
P/E Ratio:
-7.689
EPS:
-3.0004
Net Cash Flow:
$-370.18M
1W Performance:
-11.98%
1M Performance:
-17.84%
6M Performance:
+457.25%
1Y Performance:
+511.13%
1-Day Range:
$22.08
$23.30
1-Week Range:
$22.08
$26.33
52-Week Range:
$2.7601
$30.60
Alumis Inc Stock (ALMS) Company Profile
Name
Alumis Inc
Sector
Industry
Phone
650-231-6625
Address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
23.07 | 2.93B | 24.05M | -243.33M | -370.18M | -3.0004 |
VRTX
Vertex Pharmaceuticals Inc
|
448.62 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
741.69 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
677.50 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
308.05 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
275.69 | 30.60B | 5.36B | 287.73M | 924.18M | 2.5229 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-26 | Initiated | Raymond James | Strong Buy |
| Feb-25-26 | Initiated | Stifel | Buy |
| Jan-21-26 | Initiated | Chardan Capital Markets | Buy |
| Jul-25-25 | Initiated | Wells Fargo | Overweight |
| Jun-10-25 | Resumed | Guggenheim | Buy |
| Jan-30-25 | Initiated | Oppenheimer | Outperform |
| Oct-31-24 | Initiated | Robert W. Baird | Outperform |
| Oct-17-24 | Initiated | H.C. Wainwright | Buy |
| Jul-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-23-24 | Initiated | Guggenheim | Buy |
| Jul-23-24 | Initiated | Leerink Partners | Outperform |
| Jul-23-24 | Initiated | Morgan Stanley | Overweight |
View All
Alumis Inc Stock (ALMS) Latest News
Alumis (NASDAQ:ALMS) Shares Down 5.8%Here's What Happened - MarketBeat
Why Alumis Inc. Stock Is Suddenly Sinking - TipRanks
Aug PostEarnings: Can Alumis Inc ride the EV wave2026 Highlights & Reliable Volume Spike Alerts - baoquankhu1.vn
Chardan Capital initiates coverage of Alumis (ALMS) with buy recommendation - MSN
Alumis Inc. (ALMS) Receives a Buy from Morgan Stanley - The Globe and Mail
Short Covering: Is Alumis Inc gaining market shareJobs Report & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Alumis (ALMS) Q4 Loss Of US$92.9 Million Tests Bullish Growth Narrative - simplywall.st
Alumis (ALMS) Sees Price Target Raised by Morgan Stanley | ALMS Stock News - GuruFocus
Alumis (NASDAQ:ALMS) Price Target Raised to $38.00 - MarketBeat
Alumis (NASDAQ:ALMS) Given New $38.00 Price Target at Chardan Capital - MarketBeat
Alumis Reports Positive Phase 3 Results for Envudeucitinib in Psoriasis, Financial Highlights, and 2026 Milestones - Minichart
ALMS Earnings History & Surprises | EPS & Revenue Results | ALUMIS INC (NASDAQ:ALMS) - ChartMill
Alumis (NASDAQ:ALMS) Issues Quarterly Earnings Results - MarketBeat
[S-3ASR] ALUMIS INC. SEC Filing - Stock Titan
Alumis : Corporate PresentationMarch 2026 - marketscreener.com
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements - The Manila Times
Alumis 2025 10-K: $24.05M revenue, $(2.86) EPS (loss) - TradingView
Alumis (NASDAQ: ALMS) advances TYK2 pipeline and closes $238M ACELYRIN stock merger - Stock Titan
Alumis (ALMS) details 2025 results, envudeucitinib NDA plan and cash raise - Stock Titan
A psoriasis pill hit late-stage goals; Alumis plans U.S. filing in 2026 - Stock Titan
Alumis presents phase 3 psoriasis trial data at dermatology meeting By Investing.com - Investing.com India
**Key Clinical Data to Be Revealed Soon** Biopharmaceutical company Alumis Inc. announced that the phase III clinical trial data of its lead candidate drug Envudeucitinib for the treatment of moderate-to-severe plaque psoriasis has been selected for the "Lat - Bitget
**Key Clinical Data to Be Revealed Soon** Biopharmaceutical company Alumis Inc. announced that the phase III clinical trial data of its lead candidate drug Envudeucitinib for the treatment of moderate to severe plaque psoriasis has been selected for the "Lat - Bitget
Alumis presents phase 3 psoriasis trial data at dermatology meeting - Investing.com
Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting - The Manila Times
Experimental oral psoriasis drug’s Phase 3 results to debut at skin conference - Stock Titan
Huge insider buying now at this insurance giant and 2 biotechs - MSN
Alumis (NASDAQ:ALMS) Trading Down 3.5%Here's What Happened - MarketBeat
ALMS Technical Analysis & Stock Price Forecast - Intellectia AI
Wells Fargo Initiates Coverage of Alumis (ALMS) with Overweight Recommendation - MSN
Alumis Inc. (NASDAQ:ALMS) Sees Significant Drop in Short Interest - MarketBeat
Alumis Inc. (ALMS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Alumis Inc expected to post a loss of 98 cents a shareEarnings Preview - TradingView
Inflation Data: Can Alumis Inc ride the EV waveGold Moves & Low Risk Investment Opportunities - baoquankhu1.vn
Raymond James initiates coverage of Alumis (ALMS) with strong buy recommendation - MSN
Raymond James Starts ALMS (Alumis Inc. Common Stock) at Strong Buy Mar 2026 - Meyka
Alumis (NASDAQ:ALMS) Stock Price Down 6.7%Should You Sell? - MarketBeat
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga
Assessing Alumis (ALMS) Valuation After A Strong Multi‑Month Share Price Run - Yahoo Finance
Raymond James initiates Alumis stock coverage citing psoriasis drug potential - Investing.com Nigeria
Raymond James initiates Alumis stock coverage citing psoriasis drug potential By Investing.com - Investing.com South Africa
Alumis Teases TYK2 Catalysts at Leerink: Phase III Psoriasis Wins, NDA Plan and Lupus Readout Ahead - Yahoo Finance
TYK2 Validation and Expanding Indications Drive Buy Rating and $40 Price Target for Alumis - TipRanks
Certain Options of Alumis Inc. are subject to a Lock-Up Agreement Ending on 9-MAR-2026. - marketscreener.com
Phase III wins lift Alumis, Corcept shares in January - bioworld.com
Alumis to Present at the Leerink Partners Global Healthcare Conference - The Manila Times
ALMS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Biopharma CEO to appear in live Leerink healthcare fireside chat - Stock Titan
Alumis Inc. (NASDAQ:ALMS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Alumis Shares Phase 3 Psoriasis Details, Targets 2H NDA Filing at Oppenheimer Healthcare Conference - Yahoo Finance
ALMS SEC FilingsAlumis Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Alumis Inc Stock (ALMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.80%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):